Disarming an electrophilic warhead: Retaining potency in Tyrosine Kinase Inhibitor (TKI)-resistant CML lines, while circumventing pharmacokinetic liabilities

Pharmacologic blockade of STAT3 activation in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cell lines characterized by kinase-independent resistance re-sensitized CML cells to TKI therapy, suggesting that STAT3 inhibitors in combination with TKIs are an effective combinat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ChemMedChem
Main Authors: Ali, Ahmed M., Gómez-Biagi, Rodolfo F., Rosa, David A., Lai, Ping-Shan, Heaton, William L., Park, JiSung, Eiring, Anna M., Vellore, Nadeem A., de Araujo, Elvin D., Ball, Dan P., Shouksmith, Andrew E., Patel, Ami B., Deininger, Michael W., O’Hare, Thomas, Gunning, Patrick T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963206/
https://ncbi.nlm.nih.gov/pubmed/27028877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados